Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023
A live audio webcast of the event can be found here. The webcast will also be available on the investor page of Intercept’s website as an audio archive for approximately four weeks following the presentation.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and severe alcohol-associated hepatitis (sAH). For more information, please visit www.interceptpharma.com or connect with the Company on Twitter and LinkedIn.
For more information about Intercept, please contact:
Source: Intercept Pharmaceuticals, Inc.